| Ytd | 20.02% | |
| 1y | 9.04% |
| Open | 361.21 | Prev Close | 350.84 | Low | 358.24 | High | 367.00 | Mkt Cap | 41.31B |
| Vol | 166.81K | Avg Vol | 373.27K | EPS | 5.58 | P/E | 65.44 | Forward P/E | 34.00 |
| Beta | 0.51 | Short Ratio | 3.59 | Inst. Own | 33.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 343.13 | 200-d Avg | 318.13 | 1yr Est | 432.80 |
ONC News
BeiGene (NASDAQ:ONC) held its second-quarter earnings conference call on Wednesday. Below is the com
BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcr
Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from
https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-wi
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today anno
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemother
FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positiv
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (F
Partnership serves low- and middle-income countries, with the program projected to support approxima
Companies also enter a separate regional rights agreement granting BeOne exclusive development and c
TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the pr
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai
Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises t
Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform
BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.300 billion-$6.500 billion to $6.60
BeiGene (NASDAQ:ONC) reported quarterly earnings of $3.84 per share which beat the analyst consensus
JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises
The expansion will increase BeOne's production capacity to manufacture its medicines and is expe
Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and lowers
Jefferies analyst Faisal Khurshid upgrades BeOne Medicines (NASDAQ:ONC) from Hold to Buy and rais
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai
Citizens analyst Reni J. Benjamin reiterates BeOne Medicines (NASDAQ:ONC) with a Market Outperfor
BeOne Medicines reported positive Phase 3 BRUKINSA data in mantle cell lymphoma, reducing progressio
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today anno
As previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. (the "
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today anno
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and
Summit Therapeutics' new ivonescimab trial results showed a survival benefit in lung cancer and
BeOne Medicines Ltd. ("BeOne") (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology c
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today annou
FDA grants accelerated approval to BeOne's BEQALZI for relapsed mantle cell lymphoma after prior
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and
Guggenheim analyst Michael Schmidt maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises t
Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises
Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and ra
BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.200 billion-$6.400 billion to $6.30
BeiGene (NASDAQ:ONC) reported quarterly earnings of $3.24 per share which beat the analyst consensus
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4
The FDA accepted Summit Therapeutics' application for its lung cancer drug ivonescimab, setting
Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HE